TERMINATION OF SUBLEASETermination of Sublease • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
Contract Type FiledFebruary 25th, 2021 Company IndustryTHIS TERMINATION OF SUBLEASE (this "Agreement") is dated as of November 11, 2020, between TREX ENTERPRISES CORPORATION, a California corporation ("Sublessor"), and ANAPTYSBIO, INC., a Delaware Corporation (“Sublessee”) (collectively “Parties”).
AMENDMENT NO. 3 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
Contract Type FiledFebruary 25th, 2021 Company IndustryThis Amendment No. 3 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of October 23, 2020 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party”.
CONFIDENTIAL SETTLEMENT AND MODIFICATION AGREEMENTSettlement and Modification Agreement • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 25th, 2021 Company Industry JurisdictionThis Confidential Settlement and Modification Agreement (the “Agreement”) is made and entered into on the date that it is signed by the last of the signatories identified below (the “Effective Date”), by and between (i) AnaptysBio, Inc., a Delaware corporation having its principal place of business at 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (“AnaptysBio”), (ii) Tesaro, Inc., a Delaware corporation having its principal place of business in 1000 Winter Street, Waltham, Massachusetts 02451, (iii) Tesaro Development, Ltd., a Bermuda corporation having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with Tesaro, Inc., “Tesaro”), and (iv) GlaxoSmithKline LLC, a Delaware limited liability corporation having its principal place of business at 5 Crescent Drive, Philadelphia, PA 19112 (“GSK”) (Tesaro and GSK, collectively, “Defendants”) (each individually the “Party” or collectively the “Parties”).